The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy
- Status
- UNKNOWN
- Phase
- PHASE1
Clinical Trials Related to Non-small Cell Lung Cancer
Related studies linked through entity extraction aliases.
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Total-body PET/CT Imaging Using the uEXPLORER in Non-small Cell Lung Cancer Patients Treated by Induction Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiotherapy
- Status
- COMPLETED
- Phase
- N/A
Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
- Status
- RECRUITING
- Phase
- N/A
Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Efficacy and Safety of Camrelizumab in Real-World Study
- Status
- UNKNOWN
- Phase
- N/A
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
- Status
- TERMINATED
- Phase
- PHASE1
Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- N/A
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
- Status
- SUSPENDED
- Phase
- PHASE2